DMA drug combination in old mice: senescent and cancer cells, lifespan
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description presents a paper on DMA, a combination of dichloroacetate, metformin and a 10-fold reduced Navitoclax dose, which targeted senescent and cancer cells in vitro and extended lifespan in old mice after prolonged dosing. [1]
Navitoclax's clinical use was limited by dose-dependent thrombocytopenia and tumor-specific resistance, so the authors combined dichloroacetate and metformin with a 10-fold reduced Navitoclax dose, termed DMA. [1]
DMA ablated different types of senescent and cancer cells in vitro by exacerbating their ATP production defects, and healthy human cells tolerated it. [1]
In aged mice, acute DMA improved functional performance and prolonged dosing extended lifespan; the in vivo effects are yet to be fully explored. [1]
DMA aims at shared metabolic weaknesses
According to the description, the paper asks whether senescent and cancer cells can be attacked together through metabolic vulnerabilities. Navitoclax alone showed senolytic and antitumor activity, but its clinical use was limited by dose-dependent thrombocytopenia (low platelets) and tumor-specific resistance. The authors therefore combined dichloroacetate and metformin with a 10-fold reduced Navitoclax dose, calling this pharmacology DMA. [1]
In vitro ablation and old-mouse lifespan
The description reports that DMA effectively ablated different types of senescent and cancer cells in vitro by worsening their defects in ATP production. Healthy human cells tolerated the treatment, as did mice in vivo. In aged mice, acute administration improved functional performance, and prolonged dosing extended lifespan. These are described results from the paper, not established human benefits. [1]
In vivo effects still to be fully explored
The description states that the in vivo effects of DMA are yet to be fully explored. The authors suggest DMA might represent a new, clinically viable way to combat cancer and senescence without toxicity to healthy cells and tissues. That is a suggestion in the description, not a demonstrated clinical result; the description does not report human trials, dosing for people or safety confirmation. [1]
Context & limits
This explainer is based only on the supplied video description, which summarizes the paper's abstract; the video and transcript were not reviewed, and no full text was examined. The description reports in vitro and mouse results and a suggestion of clinical viability, not human trials or confirmed safety.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
10-fold reduced dose of Navitoclax
exacerbating their defects in ATP production
extends lifespan after prolonged dosing
About this video
Creator description · original textText language: English
Aging Journal · 36 min · Source published: 2026-10-15
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.